Discovery of VU6066098: A Selective and CNS-Penetrant mGlu 2 NAM with Robust Antidepressant-, Antipsychotic-, and Procognitive-like Activity in Rodents
Open Access
- 23 June 2026
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (14) , 2730-2738
Abstract
Herein, we report the discovery and development of an optimized mGlu2 Negative Allosteric Modulator (NAM) in vivo tool compound, VU6066098, based on a novel, structurally distinct chemotype. VU6066098 is a potent, selective, and CNS-penetrant mGlu2 NAM with excellent rat PK (CLp = 23.9 mL/min/kg, t1/2 = 2.2 h, %F = 100, Kp = 1.28, Kp,uu = 0.25), making it ideal to explore the therapeutic potential of selective mGlu2 inhibition in preclinical rat models. In a rat forced swim test, VU6066098 displayed an oral minimum effective dose (MED) of 1 mg/kg and was equi-efficacious to ketamine. In amphetamine-induced hyperlocomotion, VU6066098 displayed an oral minimum effective dose (MED) of 30 mg/kg. While in the preclinical cognitive tasks of rat novel object recognition and acquisition of contextual fear conditioning, VU6066098 produced robust dose-dependent effects at oral minimum effective doses (MED) of 3 mg/kg and 0.3 mg/kg, respectively. In a blast-related traumatic brain injury (TBI) model, administration of VU6066098 at a dose of 10 mg/kg IP was effective acutely, and the effect on NOR memory was sustained up to 30 days postdose. Thus, mGlu2 NAMs show therapeutic potential for the treatment of a broad range of affective and cognitive symptoms associated with Major Depressive Disorder, Alzheimer’s disease, TBI, and acute psychosis; moreover, these data strongly support further optimization of mGlu2 NAMs for future clinical development.Keywords
Funding Information
- Health Services Research and Development (1I01BX005882)
- Health Services Research and Development (1I01RX003846)
This publication has 40 references indexed in Scilit:
- mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical developmentEuropean Archives of Psychiatry and Clinical Neuroscience, 2023
- The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice modelJournal of Psychiatric Research, 2020
- Relationship of traumatic brain injury to chronic mental health problems and dementia in military veteransNeuroscience Letters, 2019
- mGlu2/3 receptor antagonists2019
- Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAMBioorganic & Medicinal Chemistry Letters, 2012
- Distribution and abundance of metabotropic glutamate receptor subtype 2 in rat brain revealed by [3H]LY354740 binding in vitro and quantitative radioautography: Correlation with the sites of synthesis, expression, and agonist stimulation of [35S]GTPγs bindingJournal of Comparative Neurology, 2005
- Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer’s diseaseActa Neuropathologica, 2004
- Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressantsPsychopharmacology, 1995
- Immunohistochemical localization of metabotropic glutamate receptors, mGluR2 and mGluR3, in rat cerebellar cortexNeuron, 1994
- Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the ratNeuroscience, 1993